

# ACS WEBINARS - March 2017

April 13, 2017

## The Good, The Bad and the Uncertain: Public Perception of the Chemical Enterprise

Part three of the [2017 Industrial Science Series](#)



Chemistry enables the best of the modern world, keeping us better fed, more healthy and with more leisure activities than at any time in history. Yet, we live in a time when much of society is averse to chemicals. Mark Jones will join us to share some examples of good done by the chemical enterprise and lead a discussion of the origin of chemistry's bad reputation. Chemists, dating back to the

alchemists, expand what is possible in nature and, in so doing, made great improvements. Unpleasant surprises have come with the advances, fueling negative views of chemistry. More commonly, ambiguity in what constitutes acceptable risks creates uncertainty that taints the enterprise. Chemistry's unique position as the only science that alters the natural world is changing. Chemists, with centuries of experience, provide the experience base to guide future development.

### What You Will Learn

- The origin of chemistry's negative reputation
- How we can continue advancing the science without causing harm
- Some of the advances that chemistry has made

## Webinar Details

- Date: Thursday, April 13, 2017 @ 2-3pm ET
- Fee: Free to Attend
- Download Slides: Available Day of Broadcast

## Experts



**Mark Jones**  
Dow Chemical



**William Carroll**  
Former Chair of the Board of ACS

## Co-Produced With



**ACS Committee on Corporation Associates**



**April 20, 2017**

## **Cystic Fibrosis: Treatment and Discovery of CFTR Modulators**

Session 4 of the [2017 Drug Design and Delivery Symposium](#)



How are modern day chemists seeking to treat cystic fibrosis? Join Peter Grootenhuis of Vertex Pharmaceuticals as he delivers a brief overview of the drug discovery approaches and challenges to identify small molecules CFTR modulators. These compounds improve the trafficking, processing and/or restore the function of the mutant CFTR protein and address the primary cause of

cystic fibrosis.

### **What You Will Learn**

- How misfolded mutant CFTR is partially 'fixable' by a combination of complementary drugs
- Why an open mind is required when working with CFTR modulators
- Examples of multiple HTS campaigns and medicinal chemistry efforts using phenotypic assays and cultured primary human cells from CF patients were essential to the discovery of two CFTR modulator drugs

### **Webinar Details**

- Date: Thursday, April 20, 2017 @ 2:00-3:00pm ET
- Fee: Free to Attend
- Download Slides: Available Day of Broadcast

## Experts



Peter Grootenhuis  
Vertex



Nick Meanwell  
BMS

## Co-Produced By



**aaps**<sup>®</sup>

**American Association of  
Pharmaceutical Scientists**



*Division of  
Medicinal  
Chemistry*